Beta-O2 Technologies

Beta-O₂ is a biomedical company which has created a novel technology that ingeniously enables adequate oxygen supply to cells and organs transplanted in oxygen-poor sites in the body. After review of the various applications to which this innovative technology could be utilized, the company chose to focus its initial efforts on the development of the βO₂ bioartificial pancreas (BAP), intended as a therapeutic treatment for Type I diabetes and a subgroup of Type II diabetes. A combined 40 million people suffer from these indications.

The BAP uniquely facilitates continuous oxygenation of insulin producing Islets of Langerhans by means of photosynthesizing algae. The system is contained in an immune-protected environment and can be implanted subcutaneously anywhere in the body. The Islets of Langerhans in the BAP sense glucose levels in the body and secrete the corresponding levels of insulin necessary to maintaining normal glucose levels.

While competitors are struggling without success to develop an alternative way to perpetually oxygenate islets, Beta-O₂ believes that the BAP will ignite a major revolution in the treatment of diabetes in the future.

View the Beta-O₂ Technology Demo
Requires Macromedia Flash Plugin